PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 14 | 4 | 228–234
Article title

Leczenie przyczynowe (reperfuzyjne) w ostrej fazie niedokrwiennego udaru mózgu – od pierwszych prób do dziś

Content
Title variants
EN
Causative (reperfusion) treatment in acute ischaemic stroke – from the first attempts until today
Languages of publication
EN PL
Abstracts
EN
The review presents the development of causative treatment in the acute phase of ischaemic stroke over the past 20 years. The earliest methods of brain reperfusion, still in use today, are based on intravenous administration of a thrombolytic agent, but as the protocols improved, it was possible to extend the therapeutic time window for this method from initial 3 hours up to 4.5 hours (as standard), and even up to 6 hours in selected patients. The next step of brain reperfusion evolution was local, intra-arterial administration of a thrombolytic drug, and finally mechanical intravascular procedures were developed, which allowed the therapeutic window to be extended to 8 hours. The most advanced approaches, which combine 2 or 3 methods, enable safe and efficacious treatment of the acute phase of ischaemic stroke even up to 12 hours from its onset. This creates new perspectives for a development of vascular neurology and neurointerventional radiology, which in the future will give patients suffering from acute ischaemic stroke much more chances for survival and functional recovery than it has been very recently.
PL
W artykule przedstawiono, jak w ostatnich 20 latach rozwijały się metody przyczynowego – a więc rekanalizującego – leczenia w ostrej fazie niedokrwiennego udaru mózgu. Najwcześniejsze sposoby reperfuzji mózgu, wciąż stosowane, opierają się na dożylnym podaniu środka trombolitycznego; dzięki dopracowaniu protokołów leczenia udało się poszerzyć okno terapeutyczne dla tej metody z 3 godzin do 4,5 godziny (standardowo), a w niektórych przypadkach – nawet do 6 godzin. Kolejnym etapem rozwoju metod reperfuzji mózgu było lokalne, dotętnicze podawanie leku trombolitycznego. Wreszcie pojawiły się mechaniczne procedury wewnątrznaczyniowe, pozwalające poszerzyć okno terapeutyczne do 8 godzin. Najbardziej zaawansowane podejścia, łączące dwie lub trzy metody, umożliwiają bezpieczne i skuteczne leczenie chorych nawet w ciągu 12 godzin od wystąpienia objawów udaru mózgu. Stwarza to nowe perspektywy rozwoju neurologii naczyniowej i radiologii neurointerwencyjnej. W przyszłości pacjenci doznający niedokrwiennego udaru mózgu będą zatem mieć znacznie większe szanse na przeżycie i sprawne funkcjonowanie niż jeszcze bardzo niedawno.
Discipline
Publisher

Year
Volume
14
Issue
4
Pages
228–234
Physical description
Contributors
References
  • 1. Bergen D.C., Silberberg D.: Nervous system disorders: a global epidemic. Arch. Neurol. 2002; 59: 1194-1196.
  • 2. Rosamond W., Flegal K., Furie K. i wsp.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-e146.
  • 3. Feigin V.L., Forouzanfar M.H., Krishnamurthi R. i wsp.; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group: Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245-254.
  • 4. Heuschmann P.U., Wiedmann S., Wellwood I. i wsp.; European Registers of Stroke: Three-month stroke outcome: the European Registers of Stroke (EROS) investigators. Neurology 2011; 76: 159-165.
  • 5. Donnan G.A., Davis S.M., Chambers B.R. i wsp.: Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276: 961-966.
  • 6. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial - Europe Study Group. N. Engl. J. Med. 1996; 335: 145-150.
  • 7. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multi-centre Acute Stroke Trial-Italy (MAST-I) Group. Lancet 1995; 346: 1509-1514.
  • 8. Hacke W., Kaste M., Fieschi C. i wsp.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
  • 9. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 1995; 333: 1581-1587.
  • 10. Hacke W., Kaste M., Fieschi C. i wsp.: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
  • 11. Clark W.M., Wissman S., Albers G.W. i wsp.: Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Non-interventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-2026.
  • 12. Hacke W., Kaste M., Bluhmki E. i wsp.; ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 2008; 359: 1317-1329.
  • 13. Bluhmki E., Chamorro A., Davalos A. i wsp.: Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009; 8: 1095-1102.
  • 14. Davis S.M., Donnan G.A., Parsons M.W. i wsp.; EPITHET investigators: Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008; 7: 299-309.
  • 15. Hacke W., Albers G., Al-Rawi Y. i wsp.; DIAS Study Group: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
  • 16. Furlan A.J., Eyding D., Albers G.W. i wsp.; DEDAS Investigators: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227-1231.
  • 17. Hacke W., Furlan A.J., Al-Rawi Y. i wsp.: Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009; 8: 141-150.
  • 18. IST-3 collaborative group; Sandercock P., Wardlaw J.M., Lindley R.I. i wsp.: The benefits and harms of intravenous throm-bolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379: 2352-2363.
  • 19. IST-3 collaborative group: Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol. 2013; 12: 768-776.
  • 20. Wahlgren N., Ahmed N., Davalos A. i wsp.; SITS-MOST investigators: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
  • 21. Wahlgren N., Ahmed N., Davalos A. i wsp.; SITS investigators: Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-1309.
  • 22. Ahmed N., Wahlgren N., Grond M. i wsp.; SITS investigators: Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 2010; 9: 866-874.
  • 23. Lees K.R., Bluhmki E., von Kummer R. i wsp.: Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
  • 24. Emberson J., Lees K.R., Lyden P. i wsp.; Stroke Thrombolysis Trialists' Collaborative Group: Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929-1935.
  • 25. Huang X., Cheripelli B.K., Lloyd S.M. i wsp.: Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015; 14: 368-376.
  • 26. Alexandrov A.V., Molina C.A., Grotta J.C. i wsp.; CLOTBUST Investigators: Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med. 2004; 351: 2170-2178.
  • 27. Eggers J., Koch B., Meyer K. i wsp.: Effect of ultrasound on thrombolysis of middle cerebral artery occlusion. Ann. Neurol. 2003; 53: 797-800.
  • 28. Daffertshofer M., Gass A., Ringleb P. i wsp.: Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005; 36: 1441-1446.
  • 29. del Zoppo G.J., Higashida R.T., Furlan A.J. i wsp.: PROACT: a phase II randomized trial of recombinant prourokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29: 4-11.
  • 30. Furlan A., Higashida R., Wechsler L. i wsp.: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-2011.
  • 31. Lewandowski C.A., Frankel M., Tomsick T.A. i wsp.: Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30: 2598-2605.
  • 32. IMS Study Investigators: Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35: 904-911.
  • 33. IMS II Trial Investigators: The Interventional Management of Stroke (IMS) II Study. Stroke 2007; 38: 2127-2135.
  • 34. Broderick J.P., Palesch Y.Y., Demchuk A.M. i wsp.; Interventional Management of Stroke (IMS) III Investigators: Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N. Engl. J. Med. 2013; 368: 893-903.
  • 35. Smith W.S., Sung G., Starkman S. i wsp.; MERCI Trial Investigators: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 1432-1438.
  • 36. Smith W.S., Sung G., Saver J. i wsp.; Multi MERCI Investigators: Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39: 1205-1212.
  • 37. Bose A., Henkes H., Alfke K. i wsp.; Penumbra Phase 1 Stroke Trial Investigators: The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. Am. J. Neuroradiol. 2008; 29: 1409-1413.
  • 38. Penumbra Pivotal Stroke Trial Investigators: The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009; 40: 2761-2768.
  • 39. Nogueira R.G., Lutsep H.L., Gupta R. i wsp.; TREVO 2 Trialists: Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012; 380: 1231-1240.
  • 40. Saver J.L., Jahan R., Levy E.I. i wsp.; SWIFT Trialists: Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012; 380: 1241-1249.
  • 41. Leker R.R., Eichel R., Gomori J.M. i wsp.: Stent-based thrombectomy versus intravenous tissue plasminogen activator in patients with acute middle cerebral artery occlusion. Stroke 2012; 43: 3389-3391.
  • 42. Broderick J.P., Palesch Y.Y., Demchuk A.M. i wsp.; Interventional Management of Stroke (IMS) III Investigators: Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N. Engl. J. Med. 2013; 368: 893-903.
  • 43. Kidwell C.S., Jahan R., Gornbein J. i wsp.; MR RESCUE Investigators: A trial of imaging selection and endovascular treatment for ischemic stroke. N. Engl. J. Med. 2013; 368: 914-923.
  • 44. Ciccone A., Valvassori L., Nichelatti M. i wsp.; SYNTHESIS Expansion Investigators: Endovascular treatment for acute ischemic stroke. N. Engl. J. Med. 2013; 368: 904-913.
  • 45. Berkhemer O.A., Fransen P.S., Beumer D. i wsp.; MR CLEAN Investigators: A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 2015; 372: 11-20.
  • 46. Campbell B.C., Mitchell P.J., Kleinig T.J. i wsp.; EXTENDIA Investigators: Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 2015; 372: 1009-1018.
  • 47. Goyal M., Demchuk A.M., Menon B.K. i wsp.; ESCAPE Trial Investigators: Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 2015; 372: 1019-1030.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-5a084180-9cf7-4ed4-8ea7-52da94994c78
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.